SUPPORTING INFECTIOUS DISEASE RESEARCH

Product Information Sheet for NR-2865

Peptide Arrays, Influenza Virus A/New York/348/2003 (H1N1) and A/New York/504/1998 (H3N2) PB1-F2 Proteins

Catalog No. NR-2865

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

Bio-Synthesis, Inc.

Product Description:

NR-2865 contains two peptide arrays. The first peptide array (NRC-338; 8 peptides) spans the PB1-F2 protein of the A/New York/348/2003 (H1N1) strain of influenza virus (GenPept: ABA12738). The second peptide array (NRC-339; 16 peptides) spans the PB1-F2 protein of the A/New York/504/1998 (H3N2) strain of influenza virus (GenPept: ABD15623). Peptides are 13- to 17-mers, with 11 or 12 amino acid overlaps. Please see Table 1 for length and sequence of individual peptides.

Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2). Peptides can almost always be dissolved in 100% DMSO.

Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water or 1 mL of 100% DMSO. The DMSO can be slowly diluted to a lower concentration with aqueous medium. Care must be taken to ensure that the

peptide does not begin to precipitate out of solution. For cell-based assays, 0.5% DMSO in medium is usually well-tolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution (see Table 2). These solvents may not be appropriate for certain applications, including cell-based assays.

Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5–6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Arrays, Influenza Virus A/New York/348/2003 (H1N1) and A/New York/504/1998 (H3N2) PB1-F2 Proteins, NR-2865."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898 SUPPORTING INFECTIOUS DISEASE RESEARCH

Product Information Sheet for NR-2865

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

- Ghedin, E., et al. "The NIAID Influenza Genome Sequencing Project." Direct submission (2005). GenPept: ABA12738.
- Ghedin, E., et al. "The NIAID Influenza Genome Sequencing Project." Direct submission (2006). GenPept: ABD15623.
- 3. Chanturiya, A. N., et al. "PB1-F2, an Influenza A Virus-Encoded Proapoptotic Mitochondrial Protein, Creates Variably Sized Pores in Planar Lipid Membranes." J. Virol. 78 (2004): 6304–6312. PubMed: 15163724.

 $\mathsf{ATCC}^{\circledcirc}$ is a trademark of the American Type Culture Collection.



Table 1			
Peptide	Length	Sequence	
NRC-338:	8: Influenza Virus A/New York/348/2003(H1N1)		
1 of 8	17	1 MGQEQGTPWIQSTGHIS 17	
2 of 8	17	7 TPWIQSTGHISTQKEED 23	
3 of 8	17	13 TGHISTQKEEDGQKIPK 29	
4 of 8	16	18 TQKEEDGQKIPKLEHR 33	
5 of 8	17	23 DGQKIPKLEHRNSTQLM 39	
6 of 8	17	29 KLEHRNSTQLMGHYQKT 45	
7 of 8	17	35 STQLMGHYQKTMNQVAM 51	
8 of 8	17	41 HYQKTMNQVAMPKQIVY 57	
NRC-339:	Influenza Virus A/New York/504/1998(H3N2)		
1 of 16	17	1 MEQEQGTPWTQSTEHTN 17	
2 of 16	17	7 TPWTQSTEHTNIQRRGS 23	
3 of 16	17	13 TEHTNIQRRGSGRQIQK 29	
4 of 16	17	18 IQRRGSGRQIQKLGHPN 34	
5 of 16	17	24 GRQIQKLGHPNSTQLMD 40	
6 of 16	17	30 LGHPNSTQLMDHYLRIM 46	
7 of 16	17	36 TQLMDHYLRIMSQVDMH 52	
8 of 16	17	42 YLRIMSQVDMHKQTVSW 58	
9 of 16	17	47 SQVDMHKQTVSWRLWPS 63	
10 of 16	17	53 KQTVSWRLWPSLKNPTQ 69	
11 of 16	17	59 RLWPSLKNPTQGSLRTH 75	
12 of 16	17	65 KNPTQGSLRTHALKQWK 81	
13 of 16	17	71 SLRTHALKQWKSFNKQG 87	
14 of 16	17	77 LKQWKSFNKQGWTNLLK 93	
15 of 16	17	83 FNKQGWTNLLKVARLMI 99	
16 of 16	13	89 TNLLKVARLMIGH 101	

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



Product Information Sheet for NR-2865

Table 2			
Peptide	Solubility	Solvent	
NRC-338: Infl	uenza Virus A/I	New York/348/2003(H1N1)	
1 of 8	1 mg/mL	50% acetic acid in water	
2 of 8	1 mg/mL	50% acetic acid in water	
3 of 8	1 mg/mL	50% acetic acid in water	
4 of 8	1 mg/mL	50% acetic acid in water	
5 of 8	1 mg/mL	50% acetic acid in water	
6 of 8	1 mg/mL	50% acetic acid in water	
7 of 8	1 mg/mL	50% acetic acid in water	
8 of 8	1 mg/mL	50% acetic acid in water	
NRC-339: Infl	uenza Virus A/I	New York/504/1998(H3N2)	
1 of 16	1 mg/mL	50% acetic acid in water	
2 of 16	1 mg/mL	50% acetic acid in water	
3 of 16	1 mg/mL	50% acetic acid in water	
4 of 16	1 mg/mL	50% acetic acid in water	
5 of 16	1 mg/mL	50% acetic acid in water	
6 of 16	1 mg/mL	50% acetic acid in water	
7 of 16	1 mg/mL	50% acetic acid in water	
8 of 16	1 mg/mL	50% acetic acid in water	
9 of 16	1 mg/mL	50% acetic acid in water	
10 of 16	1 mg/mL	50% acetic acid in water	
11 of 16	1 mg/mL	50% acetic acid in water	
12 of 16	1 mg/mL	50% acetic acid in water	
13 of 16	1 mg/mL	50% acetic acid in water	
14 of 16	1 mg/mL	50% acetic acid in water	
15 of 16	1 mg/mL	50% acetic acid in water	
16 of 16	1 mg/mL	50% acetic acid in water	

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

NR-2865_20JUN2014